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Abstract: Many studies have shown both the CD28—D80/86 costimulatory pathway and the PD-1—
PD-L1/L2 coinhibitory pathway to be important signals in modulating or decreasing the inflamma-
tory profile in ischemia-reperfusion injury (IRI) or in a solid organ transplant setting. The importance
of these two opposing pathways and their potential synergistic effect led our group to design a
human fusion recombinant protein with CTLA4 and PD-L2 domains named HYBRI. The objective
of our study was to determine the HYBRI binding to the postulated ligands of CTLA4 (CD80) and
PD-L2 (PD-1) using the Surface Plasmon Resonance technique and to evaluate the in vivo HYBRI
effects on two representative kidney inflammatory models—rat renal IRI and allogeneic kidney
transplant. The Surface Plasmon Resonance assay demonstrated the avidity and binding of HYBRI to
its targets. HYBRI treatment in the models exerted a high functional and morphological improvement.
HYBRI produced a significant amelioration of renal function on day one and two after bilateral warm
ischemia and on days seven and nine after transplant, clearly prolonging the animal survival in a
life-sustaining renal allograft model. In both models, a significant reduction in histological damage
and CD3 and CD68 infiltrating cells was observed. HYBRI decreased the circulating inflammatory
cytokines and enriched the FoxP3 peripheral circulating, apart from reducing renal inflammation.
In conclusion, the dual and opposite costimulatory targeting with that novel protein offers a good
microenvironment profile to protect the ischemic process in the kidney and to prevent the kidney
rejection, increasing the animal’s chances of survival. HYBRI largely prevents the progression of
inflammation in these rat models.
Keywords: costimulation; coinhibition; ischemia-reperfusion injury; kidney transplant; SPR; protein
binding affinity; innate immunity; adaptive immunity; inflammation
1. Introduction
Delayed graft function (DGF) is the clinical manifestation of ischemia-reperfusion
injury (IRI) in human renal transplantation. The clinical impact of DGF on transplant-
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related outcomes is an increase in the risk of rejection, inferior allograft function, difficult
management of immunosuppression in the early post-transplant phase, and the need for
repeated renal biopsies with their related associated complications [1–3].
IRI causes a series of humoral and cellular responses, producing complex and diverse
pathophysiological pathways of damage to the organ [4,5]. The occlusion of the arterial
blood supply leads to tissue hypoxia and the imbalance of metabolic demand, thus acti-
vating cell death programs, endothelial dysfunction, transcriptional reprogramming, the
expression of cytokines, leukocyte-endothelial adhesion, macrophage and lymphocyte
activation, and the generation of small amounts of reactive oxygen species (ROS) [6–9].
Additionally, the restoration of blood flow and reoxygenation is frequently associated
with an exacerbation of tissue injury and intense inflammatory response [10]. During
reperfusion, the restoration of oxygen levels further damages cells exposed to previous
ischemia, leading to the production of large amounts of ROS that contribute to cell mem-
brane and DNA damage. Reperfusion damage results in an autoimmune response, which
includes mostly natural antibody recognition and complement cascade activation [11]. This
induces cell death and the activation of the innate and, afterwards, the adaptive immune
system [6]. Regarding adaptive immunity, multiple roles of T cells have been described in
studies of ischemia, showing evidences in both antigen-specific and antigen-independent
mechanisms of activation [1,12,13].
Given the crucial role that costimulatory signals play in T cell-mediated immune
responses, several costimulatory pathways have been targeted using monoclonal antibodies
and fusion proteins to induce immunosuppression. Currently, it is well known that the
so-called costimulatory pathways constitute a complex set of stimulatory and inhibitory
signals which together fine-tune cell responses. To induce immunosuppression, several
of these targets have been directed [14–17]. Some studies reported that CTLA4 blocks the
costimulatory CD28 pathway by binding to the ligands CD80 and CD86. This blockade
prevents the clonal expansion of effector T cells, leading them to an anergy or apoptotic
state [18–20]. The costimulatory blocker Belatacept (a mutated version of CTLA4Ig) was
approved for immunosuppression in renal transplantation in the early 2000s. The observed
advantages of Belatacept over cyclosporine include better graft function, the preservation
of renal structure, and improved cardiovascular risk profile [21]. Concerns associated
with Belatacept are a higher frequency of cellular rejection episodes, but protocol biopsies
at 1 year showed a lower incidence of chronic allograft nephropathy with Belatacept
compared to cyclosporine [22]. According to Parsons et al., Belatacept can also reduce
Human leukocyte antigen (HLA) class I antibodies in a significant proportion of highly
sensitized recipients [23].
Recent studies have shown the immunosuppressive effects of exacerbating the coin-
hibitory pathway formed by PD-1 and the ligands PD-L1 and PD-L2 [24–28]. Early PD-1
expression has been demonstrated in renal allograft, which was considered essential to
modulate T cell expansion and cytokine production. Blocking the PD-1/PD-L1 coin-
hibitory pathway during the first week after transplantation doubled the number of PD-
1–expressing CD8 and CD4 cells infiltrating the graft, mainly in the interstitium [29].
Contrasting to PD-L1, PD-L2 is mainly expressed in the Antigen presenting cells (APC),
does not link to CD80, and seems to be more significant in terms of protection against an
ischemic or allogeneic insult [24,30–32]. Moreover, this pathway has been recently related
to the regulatory T cell induction setting, a cellular subset implicated in the immune and
inflammatory response regulation [33–35].
According to these T cell-modulating pathways, the concurrent blockade of the CD28—
CD80/86 costimulatory pathway with CTLA4 and the stimulation of the PD-1 coinhibitory
pathway with PD-L2 in the cell synapses could exert better immunosuppressive or anti-
inflammatory effects [24,36]. In this regard, our group designed a novel human fusion
protein construct to target these dual and opposite costimulatory signals. The production
of the molecule consists of gen synthesis, cloning, and transient transfection with a stable
Chinese hamster ovary (CHO) mammalian cell line. This recombinant protein design
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consists of an IgG1 FC linked to a CTLA4 molecule which is also bound to two PD-L2
molecules by polypeptide links (Figure 1).
Figure 1. HYBRI protein structure.
This dual targeting may promote T cell anergy and apoptosis, enhance T cell exhaus-
tion and T-reg expansion, and downregulate the CD80/86 expression in antigen-presenting
cells [37–39]. This might suggest that lower concentrations of CTLA4 would be needed
to inhibit the CD28—CD80/86 costimulatory synapsis. This potential dual targeting may
close a synergistic circle to exert potent anti-inflammatory and immunosuppressive effects.
We studied two experimental settings, the inflammatory environment of renal warm IRI
and the renal allogeneic transplantation with cold ischemia, to evaluate the effect of our
HYBRI protein.
2. Results
2.1. Analysis of HYBRI Binding Affinity to Murine CD80 and PD-1 Proteins Using the Surface
Plasmon Resonance (SPR) Technique
SPR analysis was used to characterize the affinity and kinetics between the HYBRI
construct and PD-1 and CD80. HYBRI was covalently bound to the CM5 sensor surface and
the analytes (CD80 and PD-1) were injected in solution over the surface at concentrations
ranging from 15.6 to 2000 nM. Sensorgrams (Figure 2) show a dose-dependent direct
interaction between the analytes and HYBRI. Affinity constants determined in the steady
state reflected a high affinity for both CD80 and PD1 binding to HYBRI (Table 1). Kinetics
analysis revealed rapid association (Ka) and dissociation (Kd) for both CD80 and PD1.
From these kinetic constants, affinity constants could be calculated (KD) and were in
good agreement with the affinity constants determined from the steady-state analysis.
Experiments were also conducted to assess the effect of the presence of PD-1 on CD80
binding to HYBRI, and there was found to be a lack of competition between the two
molecules for HYBRI [40].
Table 1. CD80 and PD1 bind to HYBRI. Affinity constants (KD) were calculated from SPR analysis in
the steady state and from the kinetics analysis.
Steady State Kinetics
ka (1/Ms) kd(1/s) KD (M)
CD80 3.72 × 10−6 1.57 × 105 5.68 × 10−1 3.62 × 10−6
PD-1 5.29 × 10−5 6.37 × 104 3.19 4.91 × 10−5
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Figure 2. Representative sensorgrams of CD80 (a) and PD1 (b) binding to HYBRI. HYBRI was bound to CM5 chip and
CD80 and PD1 serial dilutions (15.625, 31.25, 62.5, 125, 250, 500, 1000, and 2000 nM) represented in distinct colors were
injected for 90 s. Experimental data are shown as color traces and black traces represent the fitted data according to the 1:1
Langmuir binding model.
2.2. Bilateral Warm Ischemia Model in Native Rat Kidneys
2.2.1. Effects of HYBRI on Renal Function
HYBRI therapy produced a significant improvement in kidney function the following
three days after warm ischemia, with a reduction in creatinine at 24 h from 2.85 mg/dL to
1.5 mg/dL (p = 0.0002) and a reduction in urea from 192.8 mg/dL to 129.2 mg/dL for the
non-treated group to the HYBRI group, respectively (p = 0.0335, Figure 3). Interestingly,
the major difference between groups was observed on the second day after ischemia, when
both parameters began to decrease in the HYBRI group but peaked in the non-treated
group. At this point, the creatinine level of the non-treated group increased to 3.02 mg/dL
compared to the reduction to 0.89 mg/dL (p = 0.001) for the group treated with the HYBRI
protein. Furthermore, in the case of blood urea the slope on the second day continued
increasing, with a significant difference from 281.3 mg/dL in the non-treated group to
76.4 mg/dL in the HYBRI group (p = 0.0022). There were no serum creatinine and urea
level fluctuations in the sham group.
2.2.2. Renal Histopathology and Immunohistochemistry
A significant reduction in histological damage was observed from a total inflammatory
score of 6.75 in the non-treated group to 3.2 in the HYBRI group (p = 0.0021), while there
was no inflammation in the sham group (Figure 4).
Despite no significant differences, the HYBRI group showed a reduction of almost half
in CD3 infiltrating cells (from 13.2 in the non-treated group to 8 in the HYBRI group). An
enrichment of FoxP3+ infiltrating cells (Tregs) in the kidney was observed (from 0.7 in the
non-treated group to 1.3 in the HYBRI group, with a trend to significance (p value= 0.075)).
Even more, creating a ratio between infiltrating FoxP3+ cells and infiltrating CD3+ cells,
animals treated with HYBRI showed a percentage of 39.1% in contrast to 8.9% in non-
treated animals (p value= 0.069). The treatment also revealed a significant reduction
in CD68 infiltrating cells from 3.3 in the non-treated group to 1.8 in the HYBRI group
(p < 0.0001).
2.2.3. Peripheral Blood and Spleen Cell Populations
There were no significant differences between groups in a flow cytometry analysis
in spleen cell subpopulations. Regarding the Peripheral blood mononuclear cell (PBMC)
analysis, the only differences seen were in the percentage of FoxP3+ cells (Tregs) in the
CD4+ cells. These cells were expanded from 5% to 13% the next day after ischemia in the
HYBRI group. In contrast, in the non-treated group, the difference was lower, with an
initial 4% to 9% twenty-four hours after ischemia. Similar trends were observed in the
percentage of CD25+ cells in both the CD3+ and CD4+ cell subsets.
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Figure 3. Functional renal parameters throughout the ischemia-reperfusion model for all treatments,
including serum creatinine (a) and serum urea (b). Values are expressed in mg/dL. Data are expressed
as mean.
2.2.4. Circulating Inflammatory Cyto/Chemokines
The serum levels of MCP1 and RANTES (also known as CCL5) at the end of the study
decreased significantly with the HYBRI treatment. In addition, concerning the IP-10, IL-12,
and MIP-1α levels, treatment with HYBRI in ischemic kidneys significantly reduced those
cytokines to values similar to those of sham rats. A partial but non-significant reduction in
the serum IL-2 levels was also observed in the HYBRI group compared to the non-treated
rats (Figure 5).
2.2.5. Renal Gene Expression
After analyzing both the TaqMan low density array (TLDA) and Polymerase chain
reaction (PCR) techniques with a CT method analysis, a few significant differences were
observed comparing the HYBRI group with the non-treated group. In this regard, the
CTLA4 (p = 0.0133) and FoxP3 (p = 0.0435) gene expression were significantly reduced in
the non-treated group compared to the HYBRI group.
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Figure 4. Renal histopathology parameters for ischemia-reperfusion injury in the three studied
groups. Semi-quantitative inflammatory score values (a) for Hematoxylin-Eosin stain. Cells per
hpf values for renal immunofluorescence CD3+ (b) and FoxP3+ (c) kidney infiltrate, and semi-
quantitative score for CD68+ surface intensity (d). Data are expressed as a mean ± SEM. *, p < 0.05
vs. non-treated; **, p < 0.01 vs. non-treated.
In HYBRI animals, there was a trend for lower expressions of Ccl7, Ccr5, Cxcl10, Fcnb,
Ptprc, S100a6, Trl2, Tlr4, HGF, RORC, and VCAM genes compared to non-treated animals.
Interestingly, the degree of reduction in the expression of those genes in the group treated
with HYBRI led to values closer to those of the sham group, and, contrarily to non-treated
rats, they were not statistically different, thus bringing the treated kidneys closer to a
healthier genotype.
The Pathwax database results for all these genes showed that the HYBRI treatment
affected nine molecular pathways related to cellular processes, such as apoptosis, necropto-
sis, and focal adhesion (see Supplementary Material). It also affected twelve environmental
information processing-related pathways, such as cytokine–cytokine receptor interaction;
cell adhesion molecules; and NF-kappa B, MAPK, JAK-STAT, and TNF signaling path-
ways as the most relevant. Of note, HYBRI also affected thirty-three pathways related to
human diseases, with the PD-1 expression pathway as the most significant. Twenty-one
organismal systems-related pathways such as NK cell-mediated cytotoxicity; Th1, Th2,
and Th17 cell differentiation; the chemokine signaling pathway; T and B-cell and toll-like
receptor signaling pathways were also affected. The gene expression results showed that
almost all the analyzed genes are regulated in the IRI setting, but just thirteen of them are
significantly addressed by the HYBRI treatment.
2.3. Rat Allogeneic Kidney Transplant Model
2.3.1. Effects of HYBRI on Renal Function and Survival
HYBRI treatment resulted in an improvement in renal function in the allogeneic
transplant model. At the early ischemic peak 24 h after kidney transplantation, despite no
significant differences HYBRI treatment reduced the serum creatinine from 1.4 to 1.1 mg/dL
and the serum urea levels from 185.8 to 157.2 mg/dL. Furthermore, HYBRI treatment
showed a significant reduction in creatinine levels on day 7 after kidney transplantation
(p = 0.0171), when kidney function begins to decline due to allogeneic kidney rejection
(Figure 6).
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Figure 5. Circulating IL-2, IL-12, IP10, MCP1, MIP-1α, and RANTES in renal warm ischemia model
measured by Luminex assay. Data are expressed as a mean ± SEM. *, p < 0.05 vs. non-treated;
**, p < 0.01 vs. non-treated.
There were also significant mortality differences between the studied groups. The
initial number of twenty-one non-treated animals was reduced to seven at the 21st day,
representing a 33% survival rate (Figure 7). Among the surviving animals, only one lived
to the end of the study at day 90 (4.8%). The mean survival of this group was 23 days. On
the other hand, the administration of the HYBRI protein during the firsts 6 days of the
study significantly improved the animal survival up to 57 days, more than double that in
the group without treatment. This data was significant in the Log rank Mantel Cox test of
the Kaplan Meier curve. On the 21st day of the study, a survival rate of 80% of the group
was seen (p = 0.021), and this finally decreased to 30% at the end of the study at day 90, a
higher percentage than the almost 5% corresponding to the untreated group (p = 0.005).
2.3.2. Renal Histopathology and Immunohistochemistry
As seen in Figure 8, conventional kidney histology reflected a significant score reduc-
tion from 8.1 in the non-treated group to 3.5 in the HYBRI group (p < 0.001). Regarding
kidney infiltrating cells, there were significant differences in CD3+, where the mean of
24.9 cells/hpf in the non-treated group was reduced to 10.3 cells/hpf in the HYBRI-treated
group (p = 0.0237). Macrophage infiltration was also significantly reduced with HYBRI
treatment, where the mean semi-quantitative score of 2.97 in the non-treated group was
decreased to 1.94 with HYBRI treatment (p = 0.0015). Humoral effect was analyzed with
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C4d staining, and significant reductions were found with the HYBRI treatment in both
studied areas (p = 0.0287 for glomeruli and p = 0.0034 for peritubular capillary).
Figure 6. Functional renal parameters throughout the allogeneic transplant model for HYBRI treat-
ment and non-treated groups. (a) Serum creatinine and (b) serum urea levels for the initial 21 days of
the study. Values are expressed in mg/dL. Data are expressed as means.
2.3.3. Circulating Inflammatory Cyto/Chemokines
A significant reduction of up to three-fold in IP-10, RANTES, and MCP1 was observed
in rats treated with HYBRI compared with non-treated rats. Animals treated with HYBRI
had reduced MIP1α values, but they were not statistically different because there was a
huge dispersal in non-treated rats. Finally, non-significant reduction in IFNγ and IL-12
was seen (Figure 9).
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Figure 7. Survival differences with the Kaplan Meier analysis of the two studied groups in the rat
allogeneic transplant model.
Figure 8. Renal histopathology parameters for allogeneic transplant model in the two studied groups.
Semi-quantitative inflammatory score values (a) for Hematoxylin-Eosin stain. Cells per hpf values
for renal immunofluorescence CD3+ (b) and semi-quantitative score for CD68+ surface intensity (c)
and C4d kidney deposition (d). Data are expressed as a mean ± SEM. *, p < 0.05 vs. Non-treated;
**, p < 0.01 vs. Non-treated.
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Figure 9. Circulating IFNγ, IL-12, IP10, MCP1, MIP-1α, and RANTES in allogeneic transplant model
measured by Luminex assay. Data are expressed as a mean ± SEM. **, p < 0.01 vs. non-treated.
3. Discussion
Ischemia reperfusion damage is a deleterious response in acutely injured kidneys in
several clinical situations. In this setting, costimulatory lymphocyte signals have been
involved or modulated successfully [41–45]. We here show a positive modulation of both
warm renal ischemia and allograft response by means of a dual and opposite costimulatory
targeting, combining two coinhibitory receptors, CTLA4 and PDL2.
After the theoretical design of the construct and the genetic transient insertion in the
CHO mammalian cell line, HYBRI was synthesized and its in vitro activity was assessed
in the mixed lymphocyte reaction [46] with successful inhibition of T cell response. As
a first validation, the well-known SPR technique showed the great affinity of our newly
designed HYBRI protein with the CD80 and PD-1 targets, thus confirming that the binding
sites of the proteins that make up the structure do not condition their binding avidity. In
this regard, HYBRI protein presents its effective binding to both CD80 and PD-1 simultane-
ously, which indicates that HYBRI can block the CD28-CD80 costimulatory pathway while
stimulating the PD-1-PD-L2 coinhibitory pathway. These bindings are effective despite
the approximately 70% protein homology shared between species, given that HYBRI is a
fully human protein [47,48]. Consequently, these results support the protein affinity to its
designed targets, appearing as an interesting option in the inflammatory animal models
addressed in the present study. Despite the reported similar KD values of the CD80 and
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HYBRI CTLA4 interaction, the KD values of the PD-1 and HYBRI’s PD-L2 interaction are
higher than the values found in the literature [31,49–52]. Similarly to the increased affinity
of the modified PD-L2 described by Philips et al. [51], PD-L2 molecules in the HYBRI
construct may have suffered conformational changes, which might account for its increased
binding to PD-1. Nevertheless, in both rat models HYBRI shows therapeutic efficacy, which
suggests that the binding is high enough to exert biological effects.
The dual and opposite costimulatory targeting conferred by HYBRI have induced
a protective effect against the kidney warm ischemia model, as the renal function and
structure after the insult is greatly improved in the treated rats. This effect may be based
on CD80 costimulatory blocking, which reduces the macrophage and T cell migration and,
also, may promote T cell apoptosis [19,53–56]. The PD-1/PD-L2 pathway may have also
produced Treg clonal expansion and diminished the T effector cell expression [24,34,57].
These pathways appear to be well addressed by the protein, although the expressions of
these molecules and their ligands are not exclusive to the APC and T cells and, in some cases,
can be bidirectional [34]. For example, renal tubular epithelial cells (RTECs), podocytes,
and other renal cells also express CD80 and PD-L2 on their surface [58–60]. This may
suggest that the desired homeostatic effect is not specific to APCs but can also be exerted
on other semi-professional cells in antigen presentation. As ischemia is present in both
groups, it can be seen that the expansion of Tregs promoted by the administration of HYBRI
plays an essential role in homeostasis. Thus, the observed reduction in macrophages and
T cells in the kidney together with the increase in regulatory T cells indicates the cellular
modulation by the HYBRI treatment of post ischemic renal inflammatory damage. In
addition, the significant decline in circulating inflammatory-related mediators reflects the
efficacy of HYBRI in modulating the inflammatory response at the systemic level [61–64].
A daily peripheral cytometric study showed only changes between study groups
for Tregs expansion on the first day after ischemia. The results suggest that the CD25+
population experienced clonal expansion early after ischemia injury, also including the
FoxP3+ subset, but that the Tregs subset is additionally expanded with the HYBRI treat-
ment. At the end of the study, peripheral and spleen population assessment did not reveal
significant cell differences between the groups despite a significant reduction in renal
inflammatory infiltrate being found with HYBRI treatment. Thus, peripheral blood or
spleen compartments may not reflect organ parenchymal changes where there is a real
inflammatory environment with myriads of attractive and activation signals. The HYBRI
treatment modulated the kidney inflammatory status towards a more attenuated inflam-
matory response and the enrichment of the Tregs population. In the allogeneic setting
with a stronger immune response, the effect of HYBRI treatment may have offered two
benefits. On the one hand, the reduction in the inflammation derived from cold ischemia
reperfusion damage, but also an intense modulation of the adaptive response of T and
possibly B cells given the reduction in C4d deposition.
A gene array analysis showed differences between the sham group and ischemia-
reperfusion groups, but few significant differences between the non-treated and HYBRI
groups. Thus, the regulation of some of the studied genes can be observed. These genes are
related to both the inflammation and expression of cell surface proteins such as CD80 and
CD86. In this regard, the HYBRI treatment may produce a reduction in CD80 and CD86
cell surface expression, an important point in this immunomodulation strategy [19,53,54].
It is also remarkable that the protein HYBRI modifies only some of the pathways related to
IRI, despite showing a large and significant therapeutic effect in vivo.
Regarding early cold ischemia injury in the allogeneic transplant model, a slight
amelioration in renal functional parameters is observed in the group treated with HYBRI.
In this complex surgical model, it is hard to discern ischemic damage among all surgical
attritions, contrarily to the easier native warm ischemia. In this second proposed model,
however, the effect of the HYBRI protein plays an essential role in kidney rejection, where
the treated group improved the renal function on days 7 and 9 after transplantation and
prolonged the survival of animals to more than double that of non-treated rats. Recently, it
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has been shown that there is early PD-1 expression in renal allograft dynamics. Blocking
this PD-1/PD-L1 negative costimulatory pathway during the first week doubled the
number of PD-1-expressing CD8 and CD4 cells, causing terminal acute rejection [29].
These findings with an approach completely opposite to our PD-1, which activates this
negative pathway, suggest the essential role of this pathway in modulating T cell expansion
and cytokine production in the allograft setting. Similar studies with PD-L1 and PD-L2
blocking antibodies in a model of IRI also aggravated the renal damage, again suggesting
the protecting role of this coinhibitory pathway [24].
To summarize, the SPR study has shown the exquisite binding affinity of HYBRI to
both targets and the advantage of binding simultaneously in vitro. Regarding in vivo stud-
ies, the HYBRI protein may effectively mitigate damage from warm ischemia reperfusion.
In the context of the kidney transplant model, the HYBRI protein also prevents kidney
rejection even by treating animals only during the first week. Therefore, this dual and op-
posite protein effect on costimulatory pathways can promote several immunomodulatory
mechanisms, leading to protecting the kidney from multiple immunoinflammatory states.
4. Materials and Methods
4.1. HYBRI Characterization and Binding Affinity Assessment with Surface Plasmon Resonance
(SPR) Technique
Surface plasmon resonance (SPR) analyses were performed at 25 ◦C on a Biacore T200
(GE Healthcare BioSciences AB, Uppsala, Sweden). The HYBRI construct was diluted in
acetate buffer pH 5 (50 µg/mL and immobilized on a CM5 chip (GE) by amine coupling
in the active flow channels (Fc) at two different ligand densities. Briefly, the surface was
activated with a mixture of 1:1 mixture of 0.1 M NHS (N-hydroxysuccinimide) and 0.1 M
EDC (3-(N,N-dimethylamino) propyl-N-ethylcarbodiimide) at a flow rate of 5 µL/min,
followed by the injection of ligand or buffer for the active or reference channel, respectively.
Ethanolamine solution was injected in both channels in order to block the remaining
reactive groups of the surface. Analytes (recombinant murine PD-1 and CD80, R&D
systems) were prepared in PBS-P in serial dilutions (0, 15.6, 62.5, 125, 250, 500, 1000, and
2000 nM) and were injected in parallel in two active and reference channels at 30 µL/min
flow for 90 s and a dissociation time of 240 s. Blanks were included for double referencing.
Experiments were also conducted to assess the effect of PD-1 presence on the CD80 binding
to Hybri. For this, concentrations series of CD80 (0–2000 nM) in the presence of PD-1
(250 nM) were included. Kinetic and affinity constants were calculated using the Biacore
T200 evaluation software 2.0 after reference and blank subtraction, and sensorgrams were
fitted according to the 1:1 Langmuir model.
4.2. Animals and Surgical Procedures
All the procedures were performed following the Guidelines of the European Com-
mittee on Care and Use of Laboratory Animals and Good Laboratory Practice. Rats from
Charles River, Spain, were housed with 12 h dark/light cycles and at a constant temper-
ature. The animals were fed ad libitum with standard diet and water. For both ischemia
and transplant surgical models, a combined anesthesia based on ketamine (75 mg/kg),
atropine (0.05 mg/kg), and valium (5 mg/kg) was used. A single intramuscular injection
of ciprofloxacin (5 mg) was administered after the surgery.
4.3. Renal Warm Ischemia Model
In this model, Lewis rats received intraperitoneally one single dose of 20 mg/kg of
HYBRI administered 24 h before bilateral renal ischemia of 40 min (n = 10, Hybri). Non-
treated animals were used as control group (n = 10, Vehicle), and they received one single
intraperitoneal administration of 300 µL of PBS 24 h before the bilateral renal ischemia of
40 min. The sham group received neither treatment nor ischemia and only laparotomy as a
technique control group was performed (n = 3, Sham).
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Blood samples were obtained from the tail vein at time zero and on daily basis until
sacrifice on day 7 after ischemia. Animals were euthanized under anesthesia on the seventh
day, blood was obtained by aortic puncture, and the spleen and kidneys were processed.
4.4. Allogeneic Transplant Model (Cold Ischemia)
In a model of renal allotransplantation, binephrectomized Lewis rats received a single
kidney transplant from a Wistar donor rats. HYBRI group (n = 10) animals were treated
with administration of 500 µg of HYBRI intraperitoneally 2 h before transplantation and
the six following days. Non-treated (n = 21) animals were used as a control group with the
administration of 200 µL of PBS with the same schedule.
Blood samples of both groups were obtained from the tail vein at time zero and on
days 1, 3, 5, 7, 9, 11, and 14 and weekly after the transplant. Surviving animals at day 90
were euthanized under anesthesia, blood was obtained by aortic puncture, and the spleen
and kidneys were processed.
4.5. Renal Function
Renal function was analyzed daily on warm ischemia model and on days 0, 1, 3, 5, 7,
9, 11, and 14 and weekly on the allogeneic transplant model. Serum creatinine and urea
measurements were performed following Jaffe’s and GLDH reactions (Olympus Autoana-
lyzer AU400, Hamburg, Germany) in the Veterinary Clinical Biochemistry Laboratory of
Universitat Autonoma de Barcelona.
4.6. Histological and Immunohistochemistry Studies
Coronal kidney slices 1–2 mm thick were fixed in buffered 4% of formalin, paraffined,
and stained with H&E. Kidney sections from the ischemia-reperfusion study were evalu-
ated by a blinded pathologist, examining the tubular necrosis, dilation, interstitial edema,
and cellular infiltrate. Abnormalities were scored on semiquantitative scale from 0 to 4 as
follows: 0, no abnormalities; 1, changes <25%; 2, changes 25–50%; 3, changes 50–75%; and
4, changes >75%. A mean group score was attained from all the individual parameters.
For the allogeneic study, sections were analyzed by a blinded pathologist for tubulitis,
interstitial infiltration, vasculitis, glomerulitis, tubular necrosis and glomerular necrosis fol-
lowing the Banff criteria for acute/active lesions scoring, held at the Ninth Banff Conference
on Allograft Pathology in La-Coruna, Spain, on 26 June 2007.
For immunohistochemistry techniques, paraffin tissue sections were stained for CD3
(Abcam, Cambridge, UK), C4d (Hycult Biotech, Uden, Netherlands), CD68 (AbD Serotec,
Raleigh, NC, USA), and FoxP3 (Novus Biologicals, CO, USA). Sections were immune
peroxidase labeled and revealed by diaminobenzidine (Sigma, Madrid, Spain). For the
CD3, CD68, and FoxP3 measurement, at least 10 hpf were taken to analyze and count.
For the C4d measurement, a semiquantitative scale from 0 to 3 was employed. Negative
controls from immunostained-matched sections without primary antibodies were used.
4.7. Peripheral Blood and Spleen Cell Subsets Characterization by Flow Cytometry
Daily peripheral blood from warm ischemia model and blood before transplant and
on days 7 and 21 for the transplant model was collected in heparin tubes and separated
in cytometry tubes to add the antibodies and lysis buffer needed to continue with the
cytometry protocol.
Splenocytes were preserved at −80 ◦C after its isolation using the Ficoll (GE Health-
care) density gradient. Standard methods were used to thaw, wash, and recover the cells.
An incubation of 25 min in the dark at room temperature with different monoclonal anti-
bodies was performed for the cytometry technique using FACS Canto II Cytometer and the
subsequent analysis using FACS DIVA software (BD Biosciences, San Jose, CA, USA). The
antibodies were titrated, mixed, and formulated for optimal staining performance.
Cocktail T/B/NK (BD 558495) containing anti-CD3 APC, anti-CD45RA FITC, and
anti-CD161 PE for T, B, and NK cell detection; anti-CD43 PE (Biolegend 202812), anti-
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CD161 AF647 (AbD Serotec MCA1427A647), and anti-ED9 FITC (AbD Serotec MCA620F)
for monocytes detection; and anti-CD3 PerCP efluor (eBioscience 46-0030-80), anti-CD4
FITC (eBioscience 11-0040-85), anti-CD25 APC (eBioscience 17-0390-82), and anti-Fox P3 PE
(eBioscience 12-4774-42) for Tregs detection. Cell membrane and nucleus permeabilization
was needed for Tregs cytometric detection.
4.8. Measurement of Serum Levels of Inflammatory Factors by Luminex Fluorescent Assay
The determination of IFNγ, IL-2, IL-12/IL-23p40, MIP-1α (CCL3), RANTES (CCL5),
IP-10 (CXCL10), and MCP-1 (CCL2) concentrations in serum was conducted using Luminex
ProcartaPlex™ Multiplex Immunoassay (Thermo Fisher Scientific, Waltham, MA, USA)
following the manufacturer’s instructions. Results were calculated from the calibration
curves and expressed in pg/mL.
4.9. Quantification of Gene Expression in Kidneys from Warm Ischemia Model
Snap-frozen rat kidneys from the ischemia-reperfusion study were stored at—80 ◦C.
RNA samples with an A260/280 ratio of ≥1.8 were extracted using the PureLinkTM RNA
MiniKit (Invitrogen, Madrid, Spain) following the manufacturer’s instructions. For the
reverse transcription, High-Capacity cDNA reverse Transcription Kit (Applied Biosystems,
Madrid, Spain) was used following the manufacturer’s instructions.
The tissue expression of immune-inflammatory mediators was quantified by Taqman
Low Density Array microfluidic cards (ABI-PrismH-7700, Applied Biosystems, Madrid,
Spain) using the comparative CT method: Emp1/Emp3/Lgals1/Lgals3/Reln/S100a6/
S100a8/S100a9/Socs3/Socs5/Tnfrsf12a/Fcnb/CD4/CD40/CD80/CD86/Tnf/Nfkb1/Ctla4/
Tlr2/Tlr4/Tlr6/Ccl2/Ccl3/Ccl5/Ccl7/Cxcr3/Cxcl10/Cxcl11/Ccr2/Ccr3/Ccr5/Ptprc/Junb/
Igsf6/Ido2/Il2/Il9/Il10/Il15/Il17a/Tfcp2/Mapk9/Spp1/Bcl6 and eukaryotic 18S as an en-
dogenous reference.
Moreover, the expression of genes validated in recent studies from our group [1] were
quantified by TaqMan real-time PCR (Applied Biosystems, Madrid, Spain) using the compar-
ative CT method: C1qa/C1qc/C1r/C1s/CD19/CD276/CD44/Cxcl3/Cxcr4/Fas/FoxP3/
Hgf/Ifng/IL-10ra/IL-11/RORC/Socs1/Sox9/TLR8/TLR9/Tnfrsf1b/Vcam and GAPDH
as endogenous reference. Controls, which were composed of distilled water, were negative
for the target and reference genes.
A pathway analysis of single gene sets, it was set up using the online PathwaX.sbc.su.se
web server, which applies the BinoX algorithm to KEGG pathways and FunCoup net-
works [65].
4.10. Statistical Analysis
For a statistical analysis, the Student’s t-test compared two conditions, whereas the
ANOVA was employed for the comparison of multiple conditions. Repeated measures
ANOVAs were used to analyze differences in various parameters due to HYBRI treatment
throughout the follow-up. Nonparametric analysis was used as needed. For the compar-
ative CT method, the value shown is the one obtained by performing the Wilcoxon rank
sum test when comparing the data of the study treatment with the data of the control
treatment. The Kaplan-Meier method was performed and analyzed using the Mantel Cox
test for a comparison of the survival distributions in the two groups. A value of p < 0.05
was considered significant. Data are given as a mean ± s.e.m.
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